Long-term therapy with growth hormone: Bringing sagacity to SAGHE

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 1, 2012, Pages 81-83

  Sperling, Mark A ^a  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CANCER RISK; CANCER SURVIVAL; CHRONIC KIDNEY FAILURE; CREUTZFELDT JAKOB DISEASE; DEATH; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EDITORIAL; GROWTH HORMONE DEFICIENCY; HUMAN; NONHUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SHORT STATURE; TREATMENT DURATION;

HORMONE REPLACEMENT THERAPY; HUMAN GROWTH HORMONE; HUMANS; PRODUCT SURVEILLANCE, POSTMARKETING;

EID: 84855500547     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-3271     Document Type: Editorial

References (15)

1. Sam S, Frohman LA 2008 Normal physiology of hypothalamic pituitary regulation. Endocrinol Metab Clin North Am 37:1-22, vii (Pubitemid 351146628)
2. Clemmons D, Maile L, Xi G, Shen X, Radhakrishnan Y 2011 Igf-I signaling in response to hyperglycemia and the development of diabetic complications. Curr Diabetes Rev 7:235-245
3. Guevara-Aguirre J, Balasubramanian P, Guevara-Aguirre M, Wei M, Madia F, Cheng CW, Hwang D, Martin-Montalvo A, Saavedra J, Ingles S, de Cabo R, Cohen P, Longo VD 2011 Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Sci Transl Med 3:70ra13
4. Gallagher EJ, LeRoith D 2011 Minireview: IGF, insulin, and cancer. Endocrinology 152:2546-2551
5. Sperling MA, Saenger PH, Hintz R, Wilson T, Rose SR 2002 Special editorial: growth hormone treatment and neoplasia-coincidence or consequence? J Clin Endocrinol Metab 87:5351-5352 (Pubitemid 36034327)
6. Casassus B 2009 Europe: acquittals in CJD trial divide French scientists. Science 323:446
7. Taylor BE, Buchman TG 2008 Is there a role for growth hormone therapy in refractory critical illness. Curr Opin Crit Care 14:438-444
8. Wilton P, Mattsson AF, Darendeliler F 2010 Growth hormone treatment in children is not associated with an increase in the incidence of cancer: experience from KIGS (Pfizer International Growth Database). J Pediatr 157:265-270
9. Bell J, Parker KL, Swinford RD, Hoffman AR, Maneatis T, Lippe B 2010 Long-term safety of recombinant human growth hormone in children. J Clin Endocrinol Metab 95:167-177
10. Luger A, Feldt-Rasmussen U, Abs R, Gaillard RC, Buchfelder M, Trainer P, Brue T 2011 Lessons learned from 15 years of KIMS and 5 years of ACROSTUDY. Horm Res Paediatr 76(Suppl 1):33-38
11. Loftus J, Heatley R, Walsh C, Dimitri P 2010 Systematic review of the clinical effectiveness of Genotropin (somatropin) in children with short stature. J Pediatr Endocrinol Metab 23:535-551
12. Ergun-Longmire B, Mertens AC, Mitby P, Qin J, Heller G, Shi W, Yasui Y, Robison LL, Sklar CA 2006 Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor. J Clin Endocrinol Metab 91:3494-3498 (Pubitemid 44402126)
13. Rosenfeld RG, Cohen P, Robison LL, Bercu BB, Clayton P, Hoffman AR, Radovick S, Saenger P, Savage MO, Wit JM 2012 Longterm surveillance of growth hormone therapy. J Clin Endocrinol Metab 97:68-72
14. Carel J-C, Ecosse E, Landier F, Meguellati-Hakkas D, Kaguelidou F, Rey G, Coste J 2012 Long-term mortality after recombinant growth hormone therapy for isolated childhood short stature: report of the French SAGhE study. (in press)
15. Tartaglia M, Gelb BD, Zenker M 2011 Noonan syndrome and clinically related disorders. Best Pract Res Clin Endocrinol Metab 25:161-179